Call Us: 1.800.873.5297

By

New Tylenol Recall

Johnson & Johnson has announced yet another recall, this time affecting 50-count packages of Tylenol 8HR. Tylenol 8HR 50-count packages with lot number BCM155 have been recalled for trace contamination with 2,4,6-tribromoanisole, which gives off a musty, moldy smell. The chemical is not known to be toxic and no adverse effects caused by 2,4,6-tribromoanisole have […]

By

Diet Drug Meridia Pulled from U.S. Market

WASHINGTON, D.C. – Under strong pressure from the Food and Drug Administration (FDA), pharmaceutical manufacturer Abbott Laboratories submitted to a voluntary recall of its weight-loss drug Meridia. The FDA’s John Jenkins, M.D., said in a firm statement Friday that “Meridia’s continued availability is not justified,” given the minimal weight-loss benefits of the drug and the […]

By

Novartis Agrees to $422.5 Million Settlement

PHILADELPHIA – The US Attorney’s office in Philadelphia announced last Thursday that Swiss pharmaceutical company Novartis has agreed to a $422.5 million settlement resolving civil and criminal investigations by the Department of Justice into off-label and illegal marketing of its anti-seizure drug Trileptal and several medications. The federal government had accused Novartis Pharmaceuticals Inc. of […]

By

FDA Places Harsh Restrictions on Avandia

WASHINGTON, DC – The US Food and Drug Administration (FDA) announced new, severe restrictions on GlaxoSmithKline’s heavily scrutinized diabetes medication Avandia on Thursday, September 23. The European Medicines Agency announced the same day that Avandia was to be completely removed from the market in Europe. FDA’s decision has raised the profile of Avandia’s health risks, […]

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.